default author photo

José Antonio Guerrero

Medica Scientia Innovation Research (MEDSIR)

SCHOLARLY PAPERS

1

DOWNLOADS

96

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Prevention of Sacituzumab Govitecan-Related Neutropenia and Diarrhea in Patients with Her2-Negative Advanced Breast Cancer (PRIMED): An Open-Label, Single-Arm, Phase 2 Trial

Number of pages: 21 Posted: 17 Mar 2025
José Manuel Pérez-García, Maria Gion, Manuel Ruiz Borrego, Isabel Blancas, Elena López-Miranda, Salvador Blanch, Sabela Recalde, Cristina Reboredo Rendo, Xavier González, Nerea Ancizar, Serafin Morales, Patricia Cortez, Zuzanna Piwowarska, Eileen Shimizu, José Antonio Guerrero, Miguel Sampayo-Cordero, Alejandro Martínez-Bueno, Javier Cortés and Antonio Llombart-Cussac
Quiron Group - International Breast Cancer Center (IBCC), Medica Scientia Innovation Research (MEDSIR), Hospital Universitario Virgen del Rocío - Medical Oncology Department, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Complex Hospitalari Universitari Moisès Broggi, Instituto de Investigación Biomédica de A Coruña - Complexo Hospitalario Universitario A Coruña, Hospital Universitario General de Catalunya, Hospital Universitario Donostia, Hospital Universitari Arnau de Vilanova, Hospital Beata Maria Ana de Jesus, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Hospital Universitario Dexeus, Vall d'Hebron Institute of Oncology and Medica Scientia Innovation Research (MEDSIR)
Downloads 96 (709,832)

Abstract:

Loading...

Sacituzumab govitecan, triple-negative, hormone receptor-positive/HER2-negative, neutropenia, diarrhea, advanced breast cancer, loperamide, granulocyte-colony stimulating factor, G-CSF.